Hippocampal 5-hydroxytryptamine receptors: Abnormalities in postmortem brain from schizophrenic subjects

Schizophrenia Research

Volumn 71, Issue 2-3, 2004, Pages 383-392

  Scarr, Elizabeth ^a,b   Pavey, Geoffrey ^a   Copolov, David ^a,b,c   Dean, Brian ^a,b,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

CNS; Hippocampus; Human; Postmortem; Schizophrenia; Serotonin receptors

Indexed keywords

KETANSERIN; RADIOLIGAND; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN; TETRALIN DERIVATIVE;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BRAIN DYSFUNCTION; CADAVER; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BINDING; SCHIZOPHRENIA; SUBICULUM;

ADULT; AGED; AUTORADIOGRAPHY; BINDING SITES; FEMALE; HIPPOCAMPUS; HUMANS; KETANSERIN; MALE; MIDDLE AGED; RADIOLIGAND ASSAY; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SUMATRIPTAN; TETRAHYDRONAPHTHALENES;

EID: 4444318653     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.02.007     Document Type: Article

References (37)

1. Aghajanian G.K., Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology. 21:1999;16S-23S
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. vol. 4:1994;American Psychiatric Association, Washington, DC
3. Benes F.M. Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol. Psychiatry. 46:1999;589-599
4. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455
5. Crow T.J. A theory of the evolutionary origins of psychosis. Eur. Neuropsychopharmacol. 5:1995;59-63. (Suppl.)
6. Dean B., Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr. Res. 21:1996;133-139
7. Dean B., Opeskin K., Pavey G., Naylor L., Hill C., Keks N., Copolov D.L. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 64:1995;1197-1202
8. 2A receptors in Brodmann's area 9 from subjects with schizophrenia: a pathological or pharmacological phenomenon? Mol. Chem. Neuropathol. 34:1998;133-145
9. Dean B., Tomaskovic-Crook E., Opeskin K., Keks N., Copolov D. No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem. Int. 34:1999;109-115
10. Dean B., Scarr E., Pavey G., Copolov D. Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder. J. Affect. Disord. 75:2003;65-69
11. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14:2000;1-21
12. Escamilla M.A. Diagnosis and treatment of mood disorders that co-occur with schizophrenia. Psychiatr. Serv. 52:2001;911-919
13. Foster P. Neuroleptic equivalence. Pharmaceut. J. 243:1999;431-432
14. Gloor P. The Hippocampal system. The Temporal Lobe and Limbic System. 1997;325-589 Oxford Univ. Press, New York
15. Goldstein D.J., Roon K.I., Offen W.W., Ramadan N.M., Phebus L.A., Johnson K.W., Schaus J.M., Ferrari M.D. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 358:2001;1230-1234
16. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452
17. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363
18. Hill C., Keks N., Roberts S., Opeskin K., Dean B., Copolov D. Diagnostic Instrument for Brain Studies. 1999;Mental Health Research Institute, Melbourne. Ref Type: Generic
19. Hoyer D., Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain: I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res. 376:1986;85-96
20. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46:1994;157-203
21. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J. Clin. Psychopharmacol. 15:1995;4S-10S
22. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. [see comments] Neuropsychopharmacology. 8:1993;315-336
23. Kingsbury A.E., Foster O.J., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res., Mol. Brain Res. 28:1995;311-318
24. Ma Q.P. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. NeuroReport. 12:2001;1589-1591
25. Mai J.K., Assheuer J., Paxinos G. Atlas of the Human Brain. 2003;Elsevier, Amsterdam
26. Meltzer H.Y. Role of Serotonin in the Action of Atypical Antipsychotic Drugs. J. Clin. Neurosci. 3:1995;64-75
27. Naylor L., Dean B., Opeskin K., Pavey G., Hill C., Keks N., Copolov D. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J. Neural Transm.: Gen. Sect. 103:1996;749-757
28. Osterlund M.K., Overstreet D.H., Hurd Y.L. The flinders sensitive line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17beta-estradiol. Brain Res., Mol. Brain Res. 74:1999;158-166
29. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., Yung A.R., Bullmore E.T., Brewer W., Soulsby B., Desmond P., McGuire P.K. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 361:2003;281-288
30. 3H]sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors. Eur. J. Pharmacol. 295:1996;271-274
31. Pauwels P.J. 5-HT 1B/D receptor antagonists. Gen. Pharmacol. 29:1997;293-303
32. Roberts C., Price G.W., Middlemiss D.N. Ligands for the investigation of 5-HT autoreceptor function. Brain Res. Bull. 56:2001;463-469
33. Rosen W.G., Mohs R.C., Johns C.A., Small N.S., Kendler K.S., Horvath T.B., Davis K.L. Positive and negative symptoms in schizophrenia. Psychiatry Res. 13:1984;277-284
34. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 301:2003;805-809
35. Shimron-Abarbanell D., Harms H., Erdmann J., Albus M., Maier W., Rietschel M., Korner J., Weigelt B., Franzek E., Sander T., Knapp M., Propping P., Nothen M.M. Systematic screening for mutations in the human serotonin 1F receptor gene in patients with bipolar affective disorder and schizophrenia. Am. J. Med. Genet. 67:1996;225-228
36. Shirazi-Southall S., Rodriguez D.E., Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology. 26:2002;583-594
37. Wooley D.W., Shaw E. A biological and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U. S. A. 40:1954;228-231